Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy

Iio, Etsuko; Shimada, Noritomo; Takaguchi, Koichi; Senoh, Tomonori; Eguchi, Yuichiro; Atsukawa, Masanori; Tsubota, Akihito; Abe, Hiroshi; Kato, Kazúo; Kusakabe, Atsunori; Miyaki, Tomokatsu; Matsuura, Kiyotaka; Matsunami, Katsuyoshi; Shinkai, Noboru; Fujiwara, Kei; Nojiri, Shunsuke; Tanaka, Yasuhito

doi:10.1111/hepr.12898

Cited by 35 publications

(47 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This might be the reason for the different SVR rates between cirrhotic and non-cirrhotic patients (Figure 1b), since a previous study [23] showed that the NS5A RAVs lead to lower SVR12 in patient with cirrhosis. Recent reports demonstrated that the SVR rate was only 69% when treated with ledipasvir plus sofosbuvir therapy in patients with prior asunaprevir plus daclatasvir treatment [24]. Prior asunaprevir plus daclatasvir treatment is associated with failure of ledipasvir plus sofosbuvir therapy due to multiple HCV NS5A RAVs.…”

Section: Discussionmentioning

confidence: 99%

Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors

Yasui

Nakamura

Suzuki

et al. 2017

IJMS

View full text Add to dashboard Cite

The aim of this study was to characterize the treatment response and serious adverse events of ledipasvir plus sofosbuvir therapies in Japanese patients infected with hepatitis C virus (HCV) genotype 1 (GT1). This retrospective study analyzed 240 Japanese HCV GT1 patients treated for 12 weeks with 90 mg of ledipasvir plus 400 mg of sofosbuvir daily. Sustained virological response at 12 weeks post-treatment (SVR12) was achieved in 236 of 240 (98.3%) patients. Among treatment-naïve patients, SVR12 was achieved in 136 of 138 (98.6%) patients, and among treatment-experienced patients, SVR12 was achieved in 100 of 102 (98.0%) patients. In patients previously treated with peginterferon plus ribavirin with various HCV NS3/4A inhibitors, 100% SVR rates (25/25) were achieved. Two relapsers had HCV NS5A resistance-associated variants (RAVs), but no HCV NS5B-S282 was observed after they relapsed. We experienced two patients with cardiac events during treatment. In conclusion, combination of ledipasvir plus sofosbuvir for 12 weeks is a potential therapy for HCV GT1 patients. Caution is needed for HCV NS5A RAVs, which were selected by HCV NS5A inhibitors and cardiac adverse events.

show abstract

Section: Discussionmentioning

confidence: 99%

Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors

Yasui

Nakamura

Suzuki

et al. 2017

IJMS

View full text Add to dashboard Cite

show abstract

“…Hepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis C. In recent years, direct‐acting antiviral (DAA) treatment has enabled many patients to achieve sustained virological responses (SVR) . Thus, it is expected that the development of HCC will be suppressed .…”

Section: Introductionmentioning

confidence: 99%

Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct‐acting antivirals

Tamaki

Higuchi

Kurosaki

et al. 2019

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Prediction of hepatocellular carcinoma (HCC) development after sustained virological response (SVR) is clinically important, and the usefulness of noninvasive markers for prediction HCC have been reported. The aim of this study was to compare the prediction accuracy for HCC development by noninvasive markers. A total of 346 patients with chronic hepatitis C without history of HCC who achieved SVR through direct‐acting antivirals were included. Magnetic resonance elastography (MRE) and serum fibrosis markers were measured 12 weeks after the end of treatment, and the subsequent HCC development was examined. The mean observation period was 26.4 ± 7.9 months, and 24 patients developed HCC. Area under the receiver operating characteristic curve of liver stiffness by MRE, Wisteria floribunda agglutinin‐positive mac‐2 binding protein and FIB‐4 for predicting HCC within 3 years was 0.743, 0.697 and 0.647, respectively. The 1/2/3‐year rates of HCC development in patients with liver stiffness ≥3.75 KPa were 6.6%, 11.9% and 14.5%, whereas they were 1.4%, 2.5% and 2.5% in patients with liver stiffness <3.75 KPa (P < 0.001). Multivariate analysis revealed that liver stiffness ≥3.75 was an independent predictive factor for HCC development (hazard ratio, 3.51; 95% confidence interval, 1.24‐9.99). In subgroup analysis, there were 132 patients who were <73 years old and had liver stiffness <3.75 KPa, and no HCC development was observed in these patients. Diagnostic accuracy for predicting HCC development was higher in MRE than serum fibrosis markers and measurement of liver stiffness by MRE could identify patients with high and low risk of HCC development after SVR.

show abstract

“…Also, Iio et al . reported that an SVR was achieved in 18 of 26 patients (69.2%) with virologic failure during and after DCV/ASV therapy . In contrast, Suda et al .…”

Section: Discussionmentioning

confidence: 92%

Retreatment with sofosbuvir/ledipasvir with or without lead‐in interferon‐β injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir/asunaprevir therapy

Uemura

Uchida

Kouyama

et al. 2017

Hepatology Research

View full text Add to dashboard Cite

show abstract

Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy

Abstract: Prior DCV/ASV therapy is associated with failure of SOF/LDV therapy due to multiple RAVs.

Cited by 35 publications

References 23 publications

Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors

Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors

Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct‐acting antivirals

Retreatment with sofosbuvir/ledipasvir with or without lead‐in interferon‐β injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir/asunaprevir therapy

Contact Info

Product

Resources

About